title: Remission of Psoriasis in a Patient with Hepatocellular Carcinoma Treated with Sorafenib.
abstract: BACKGROUND
  Psoriasis is a chronic, immune-mediated and angiogenesis-dependent disease. Activated keratinocytes in psoriatic lesions produce pro-angiogenic cytokines, including vascular endothelial growth factor (VEGF), which binds to vascular endothelial growth factor receptor (VEGFR) and promotes cell proliferation and angiogenesis. Sorafenib (BAY 43-9006) is a molecular multikinase inhibitor of RAF kinase, platelet-derived growth factor (PDGF), VEGFR-1, -2, -3, platelet-derived growth factor receptor (PDGFR)-β and c-Kit. This molecule inhibits tumor cell proliferation and angiogenesis and it is currently approved for the treatment of hepatocellular carcinoma (HCC).
  
  
  METHODS
  We present the complete remission of resistant psoriasis in a hepatitis C virus (HCV)-infected cirrhotic patient who was treated with sorafenib, for recurrent HCC.
  
  
  CONCLUSIONS
  Several targeted therapies have demonstrated efficacy against psoriasis. More research and well-designed studies, both in novel drugs and those already marketed for other indications, are needed to determine their value as potential novel therapies for psoriasis.
authors: Second Department of Propedeutic Surgery, "Laiko" General Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
authors: Efstathios A
authors: EA
authors: Antoniou
authors: Academic Department of Gastroenterology, Ethnikon and Kapodistriakon University, School of Medical Sciences, Laikon General Hospital, Athens, Greece.
authors: Ioannis
authors: I
authors: Koutsounas
authors: Second Department of Propedeutic Surgery, "Laiko" General Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece x_damaskos@yahoo.gr.
authors: Christos
authors: C
authors: Damaskos
authors: First Department of Internal Medicine, Sismanogleion General Hospital, Athens, Greece.
authors: Sotiris
authors: S
authors: Koutsounas
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D049109:Cell Proliferation / Q000187:drug effects; D016174:Hepacivirus / Q000187:drug effects / Q000472:pathogenicity; D006526:Hepatitis C / Q000150:complications / Q000473:pathology / Q000821:virology; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects / Q000473:pathology; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D008297:Male; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D012074:Remission Induction; D000077157:Sorafenib; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000235:genetics
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000077157:Sorafenib; D040281:Vascular Endothelial Growth Factor Receptor-1
keywords: Psoriasis; carcinoma; hepatocellular; skin; sorafenib; targeted